The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.

Transactions / D•• P•••••

S•••••• acquires D•• P••••• to enhance regulatory expertise and broaden its biopharma capabilities

Add-on acquisitionannouncedadd-onannounced Sep 10, 2025Fact
What happened
Target
D•• P•••••
Platform
S••••••add-on basis: S•••••• acquires D•• P••••• to enhance regulatory expertise and broaden its biopharma capabilities | S•••••• is held by K•••••••• C•••••• on its portfolio page; published on K•••••••• C••••••'s own news page
Control
Control
Share acquired
unknown
Industry
healthcare / pharma
Target location
unknown
Seller kind
unknown
Rollover
unknown
Values, only where disclosed
Enterprise value
Not disclosed
Purchase price
Not disclosed
Equity value
Not disclosed
Target revenue
Not disclosed
Target EBITDA
Not disclosed
Multiple
Not disclosed
Parties and roles
5 named
Buy side
  • S••••••Platformconfirmed
    “S•••••• acquires D•• P••••• to enhance regulatory expertise and broaden its biopharma capabilities | S•••••• is held by K•••••••• C•••••• on its portfolio page; published on K•••••••• C••••••'s own news page”
  • K•••••••• C••••••Sponsorconfirmed
    “S•••••• acquires D•• P••••• to enhance regulatory expertise and broaden its biopharma capabilities | S•••••• is held by K•••••••• C•••••• on its portfolio page; published on K•••••••• C••••••'s own news page”
Side not stated
  • G•••••••• J•••••Managementconfirmed
    “G•••••••• J•••••, CEO of S••••••, commented: “ This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum.”
  • K••• G••••Managementconfirmed
    “K••• G••••, Founder and CEO of D•• P•••••, added: “ This is an exciting new chapter for D•• P•••••.”
  • D•• P•••••Targetconfirmed
    “S•••••• acquires D•• P••••• to enhance regulatory expertise and broaden its biopharma capabilities”
Evidence
“S•••••• acquires D•• P••••• to enhance regulatory expertise and broaden its biopharma capabilities”
Press release wires (PR Newswire, GlobeNewswire, Business Wire public pages and RSS)confidence 80%recorded Sep 15, 2026